83 results on '"Brunelli, M"'
Search Results
2. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
3. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
4. 1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study
5. First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial
6. The American Society of Anesthesiologists’ (ASA) physical status system classification predicted the risk of postoperative complications at hospital discharge in 1329 consecutive patients treated with radical prostatectomy for clinical prostate cancer
7. Assessment of functional impairment and cognitive status in patients undergoing radicalcystectomy: correlation between barthel index and perioperative outcomes
8. ABO blood group and unfavorable prostate cancer features after radical prostatectomy: retrospective study on 1149 patients
9. Impact of abdominal aortic atherosclerotic burden in patients submitted to partial nephrectomy: A pilot study on 142 cases
10. Upstaging after radical prostatectomy in clinically localized intermediate and high-risk prostate cancer: The role of obesity
11. Predictors of prostatic chronic inflammation and prostate cancer risk at baseline random biopsies: Results from a large population of caucasian patients
12. 802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study
13. Nanofiber membranes as biomimetic and mechanically stable surface coatings
14. Overweight-obese patients harbor multiple prostate cancer lymph node invasion and low testosterone levels: Results from 361 consecutive caucasian patients underwent radical prostatectomy and extended pelvic lymph node dissection
15. P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial
16. Exploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
17. Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers
18. Structural and electronic changes in graphite fluorides as a function of fluorination rate: An XRS, PDF and DFT study
19. Experimental model of an artificial pneumoperitoneum to measure thermal spread during bipolar cauterizing
20. Oil Red O Is a Useful Tool to Assess Donor Liver Steatosis on Frozen Sections During Transplantation
21. A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC)
22. Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
23. P2.04-12 A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.
24. Validation of the 2009 TNM Version in a Large Multi-Institutional Cohort of Patients Treated for Renal Cell Carcinoma: Are Further Improvements Needed?
25. Body Mass Index (BMI) is an independent factor associated with the risk of multiple lymph node invasion in patients undergoing extended pelvic dissection during robot assisted radical prostatectomy
26. Experimental model of an artificial pneumoperitoneum to measure thermal energy spread during bipolar cauterizing
27. 073_17092p Effects Of Ensite Navx/Precision™ Compared To Carto®3 On Fluoroscopy Exposure And Procedural Duration In Avnrt Catheter Ablation
28. A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)
29. Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target
30. Addressing the best treatment for non-clear cell renal cell carcinoma (nccRCC): a meta-analysis of randomized clinical trials comparing VEGFR-TKis versus mTORi targeted therapies
31. 073_17093p Effects Of Different 3D Electro-Anatomic Mapping Systems On Fluoroscopy Exposure And Procedural Duration In Typical Atrial Flutter Ablation
32. PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC)
33. Feasibility and safety of not placing a drain in the pelvic cavity after robot-assisted radical prostatectomy with or without extended pelvic lymph node dissection: Results of a randomized controlled study
34. ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model
35. Short bursts of cyclic mechanical compression modulate tissue formation in a 3D hybrid scaffold
36. Fast Chromotrope Aniline Blue Special Stain Is a Useful Tool to Assess Fibrosis on Liver Biopsy During Transplantation
37. Mechanical response of 3D Insert® PCL to compression
38. RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model
39. Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC)
40. Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model
41. Prognostic impact of Ki67 for resected early stage pure Invasive Lobular breast Cancer (ILC): cut-off analysis and clinical validation
42. The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors
43. Autophagy and transplantation: organ injury and cancerogenesis by molecular expression of LC3B
44. Clinical and pathological predictors of Advanced Breast Carcinoma with Luminal subtype (ABC-Lum) identifying prognostic ‘outliers’: multicenter retrospective analysis in the ‘real-world’ scenario
45. De novo renal cell neoplasia after kidney transplantation, according to the International Society of Urological Pathology (ISUP 2013) Vancouver Classification
46. Development of a risk model to identity prognostic ‘outliers’ underwent surgery for early-stage invasive lobular breast carcinoma (ILBC) according to clinical and pathological factors
47. PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
48. Risk Stratification Model for Resected Squamous Cell Lung Cancer (R-Sqlc) Patients (Pts) According to Clinical and Pathological Factors
49. Loss of Chromosomes 9P and 14Q: Re-Profiling Metastatic Tissue for Re-Targeting Patients with Metastatic Renal Cell Carcinoma
50. A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.